ANO1 and irritable bowel syndrome: Additionally, NFA inhibition of TMEM16A caused improvement of intestinal motility in the rat model of irritable bowel syndrome (IBS) [65], blocked mucus [66], and salivary production [67] and avoided airway hyperresponsiveness in ovalbumin‐sensitized mice [68], suggesting promises for future application in pathological conditions, including IBS [65], airway mucus secretion [66], chronic asthma [68], and high salivary production [67].